Biotech flipper John Edwards joins Verseau as CEO after overseeing Tilos from birth to Merck buy

Tumor-attacking biotech Verseau Therapeutics has named a new CEO with a track record of moving biotechs from startup to M&A exit.

John Edwards, who previously served as executive chair of Tilos Therapeutics, has joined Verseau, which focuses on cancer immunotherapies that reprogram the tumor microenvironment to attack tumors.